Dr. Allen Davidoff, Ph.D.: President and CEO
Dr. Allen W. Davidoff, Ph.D. (15 years drug development ), Formerly, Chief Scientific officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (7 yrs) ( Trillium TRIL:NASDAQ). Prior to Stem Cell Therapeutics Corp., Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp. Allen has a broad range of clinical and regulatory experience. Senior management experience in pharmaceutical R&D including 2 investigational new drug (“IND”) applications or supplemental IND’s, 2 phase I studies (4 multi-country), 7 phase II studies, and 1 NDA. 12 years C- level leadership as Co-founder of Stem Cell Therapeutics Corp (Trillium Therapeutics) – A NASDAQ listed Company and XORTX Therapeutics Inc. ( XRX-CSE)
Dave Matthews, CMA, MBA, Chief Financial Officer
Dave has spent the last 25 years in senior finance roles in the life sciences and technology sector working with companies ranging from start-ups through to large, profitable multinationals in North America and Europe, including Aspreva Pharmaceuticals, Genome DX, and Contextual Genomics Inc. Dave has extensive capital markets experience having completed numerous IPO’s, follow on financings and private financings, raising over $500 million of equity and debt with the companies he’s been involved with. Dave has an MBA from Clarkson University and is a Certified Management Accountant.
Brian Mangal, MsC. BioStatistics: Director Business Development, Product Development
Brian Mangal, MsC. (12 years of clinical development experience) was formerly, Director of Biostatistics for Cardiome Pharma Corp, and responsible for all biometric activities related to the advancement of Cardiome’s clinical programs. Clinical development experience includes design, analysis and reporting on over 50 clinical trials, three FDA submissions, one TPD submission, a successful EMEA submission. Prior to Cardiome, worked on building a CRO – Everest Clinical Research, specializing in dealings with NIH in the US and as a Biostatistician at Pharmacia/Pfizer, worked on the successful sNDA for Linezolid and numerous successful trials with Celecoxib.
Dr. Alan Moore, Founding Board Member, Executive Consultant: Clinical and Regulatory Affairs
Dr. Alan F. Moore, Ph.D. Dr. Moore has extensive clinical development experience and 23 years of senior management experience in pharmaceutical R&D. During his esteemed career, he has completed 11 investigational new drug (“IND”) applications or supplemental IND’s, 15 phase I studies, 12 phase II studies, 7 phase III studies and 2 new drug applications. Most recently CEO of BetaStem Inc.